Navigation Links
GeoVax Labs' CEO Update Letter to Shareholders
Date:1/9/2012

and the U.S. Military HIV Research Program heralded a preventative vaccine that gave protection in non-human primates, a result similar to what GeoVax published earlier last year. This report confirmed the prime-boost approach plus the use of similar genetic material in the vaccine to induce a protective immune response. In essence, they have validated our concepts and added some good news to the field. Results like this give the industry hope that an effective HIV vaccine is not far from reality and bolster our confidence that we are on the right track.

Financing and Corporate Development

We continue to benefit from tremendous financial, operational, and technical support provided to us by the NIH and the HVTN. The HVTN, funded by the NIH, is the largest worldwide clinical trials network dedicated to development and testing of promising HIV/AIDS vaccines. To date, the HVTN has conducted and funded all of our clinical trials for the preventative version of our vaccine. In addition to this support from the HVTN, we are the recipient of a $20 million Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institute of Allergy and Infectious Disease (NIAID). This five-year grant spans a period from September 2007 through August 2012, providing financial support for the development of the GM-CSF adjuvanted version of our preventative vaccine.

While we are deeply appreciative of the generous governmental support we receive, it does not cover the cost of all of our activities. Hence, fundraising will continue to be a primary and critical focus for 2012, as it was in 2011. Through our efforts during 2010 and 2011 we have developed numerous contacts and raised our exposure profile among potential institutional investors which we believe will benefit us going forward. In addition to our equity financing efforts, we will continue to seek out additional opportunities for non-dilutive financing through govern
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
2. GeoVax Phase 2a Clinical Trial Completes Enrollment
3. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
4. GeoVax Labs, Inc. Announces Second Quarter Financial Results
5. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
6. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
7. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
8. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
9. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
10. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
11. GeoVax Labs Engages The Investor Relations Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , and DURHAM, N.C. , July ... today announced its acquisition of assets related to the ... PFE ) that had previously been obtained as part ... also acquired all of Pfizer,s rights to the "Icagen" ... brand and will provide comprehensive services for ion channel ...
(Date:7/2/2015)... TOKYO , July 2, 2015  Konica Minolta, ... today announced that it has acquired Sawae Technologica Ltda., ... Brazil , through its Brazilian healthcare ... . Local Brazil ... increasing population exceeding 200 million, significant healthcare ...
(Date:7/2/2015)... 2, 2015  The Commission for Certification in ... an organization that represents pharmacists in acute and ... continuing education for recertification of Certified Geriatric Pharmacists.  ... programs for this purpose.  ASHP will join the ... for the CCGP Professional Development Program. ...
Breaking Medicine Technology:Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3Commission for Certification in Geriatric Pharmacy Adds ASHP as Professional Development Program Provider 2
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that ... Food and Drug Administration for its Abbreviated New ... Powder for Solution. Perrigo is expecting to begin ... under store brand labels and is comparable to ...
... BATESVILLE, Ind., Oct. 6 Hill-Rom Holdings, Inc. (NYSE: ... has unanimously approved enhancements to the Company,s corporate ... of majority voting in uncontested elections. The ... for a majority voting standard for the election of directors ...
Cached Medicine Technology:Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350 2Hill-Rom Announces Corporate Governance Enhancements 2Hill-Rom Announces Corporate Governance Enhancements 3Hill-Rom Announces Corporate Governance Enhancements 4
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, the only ... lead a national president recruitment for Regional Care, Inc. in Scottsbluff, ... E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Erie County ... 2015 at 1:00pm. The Association welcomed speaker C. Daniel McGillicuddy Esq. of William ... practical points of investigating these types of cases. , Each year, New York ...
(Date:7/3/2015)... ... 03, 2015 , ... Talcum powder attorneys representing clients in national lawsuits announce ... Lawsuit Center website. Just as the previous version did, the new website will serve ... updates and ovarian cancer warning information. The site is routinely updated with news articles ...
(Date:7/3/2015)... ... July 03, 2015 , ... First Choice Emergency Room , the largest ... MD as the new Medical Director of its Frisco facility. , “We are pleased ... facility,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:7/3/2015)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... biblical truth and expose popular lies regarding proper relationships according to the bible. ... goes into the core of the subject by explaining why certain types of sexual ...
Breaking Medicine News(10 mins):Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2
... evidence of the H1N1 virus in animals in Africa. In one ... studied had been exposed to the H1N1 virus, commonly known as ... every pig in this village was exposed," said Thomas B. Smith, ... of the research. "Africa is ground zero for a new pandemic. ...
... , FRIDAY, Sept. 23 (HealthDay News) -- Fred Wyand has ... the public health response to human papillomavirus, or HPV. ... News , a bimonthly newsletter published by the American Social ... HPV is a sexually transmitted disease that most people ...
... -- There is a genetic link between schizophrenia and ... a new study indicates. Researchers identified 11 genetic ... which play a role in people,s risk for these ... into the causes of both conditions. "Schizophrenia and ...
... brain doesn,t stop developing at adolescence, but continues well into ... & Dentistry at the University of Alberta. It ... human brain stopped developing in adolescence. But now there is ... to medical research conducted in the Department of Biomedical Engineering ...
... CHICAGO --- A drug used to treat cancer may also ... organs or skin, such as pulmonary fibrosis or scleroderma. ... of fibrotic proteins in human cells and the development of ... to a new Northwestern Medicine study published in the journal ...
... , THURSDAY, Sept. 22 (HealthDay News) -- People with type ... an increased risk of developing pancreatitis and pancreatic cancer, a ... (exenatide) may raise the risk of thyroid cancer. Although ... noted. "We have raised concern that there may be ...
Cached Medicine News:Health News:UCLA scientists find H1N1 flu virus prevalent in animals in Africa 2Health News:UCLA scientists find H1N1 flu virus prevalent in animals in Africa 3Health News:Stress the 'Human' in HPV, One Man Suggests 2Health News:Stress the 'Human' in HPV, One Man Suggests 3Health News:Genetic Links Seen Between Bipolar Illness and Schizophrenia 2Health News:Some brain wiring continues to develop well into our 20s: U of A study 2Health News:Cancer drug may also work for scleroderma 2Health News:Popular Diabetes Drugs May Raise Pancreatic Cancer Risk, Study Suggests 2Health News:Popular Diabetes Drugs May Raise Pancreatic Cancer Risk, Study Suggests 3Health News:Popular Diabetes Drugs May Raise Pancreatic Cancer Risk, Study Suggests 4
... Streck-Kleen is an enzymatic cleanser for ... Coulter® Counters. The 475ml bottle has a ... MD Series instruments that require manual addition ... is a feature of this product. The ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
... balanced electrolyte solution manufactured for use as ... sizing. Streck-Diluent III is for use on ... JS, JT, S-Plus IV, V, VI with ... 1400 and 1600. The shelf life is ...
Streck-Detergent IIIA is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured specifically for use on the Abbott CELL-DYN® 1700 and 1800. The s...
Medicine Products: